Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia

摘要

Disclosed is the use of: (a) a vascular disrupting agent (VDA) and (b) at least one hypoxia targeting agent, in the manufacture of a medicament for the treatment of a proliferative disease; wherein the hypoxia targeting agent is Pazopanib or Bortezomib and the VDA is a compound of formula (Ib) or a salt, solvate or prodrug thereof.